- Home
- CRDO vs ROIV Comparison
CRDO vs ROIV Comparison
Compare CRDO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRDO | ROIV |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Cayman Islands | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2B | 21.0B |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRDO | ROIV |
|---|---|---|
| Price | $216.70 | $30.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | ★ $179.62 | $28.94 |
| AVG Volume (30 Days) | 5.2M | ★ 5.5M |
| Earning Date | 06-01-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 261.11 | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $436,775,000.00 | $8,260,000.00 |
| Revenue This Year | $210.92 | N/A |
| Revenue Next Year | $57.22 | $744.61 |
| P/E Ratio | $119.57 | ★ N/A |
| Revenue Growth | ★ 126.34 | N/A |
| 52 Week Low | $59.21 | $10.71 |
| 52 Week High | $213.80 | $32.79 |
Technical Indicators
Market Signals| Indicator | CRDO | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 64.41 | 56.00 |
| Support Level | $129.63 | $26.65 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 17.42 | 1.12 |
| MACD | -0.88 | 0.20 |
| Stochastic Oscillator | 98.46 | 48.05 |
Price Performance
Historical ComparisonAbout CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.